細胞番号 : 細胞名 RCB2293 : ACC-MESO-4  update : 2024/11/14
細胞特性(Comment:英)			Human malignant pleural mesothelioma cell line.
細胞特性(日)			ヒト悪性胸膜中皮腫由来細胞株（アスベスト暴露歴の疑いあり）。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)			In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Cancer Sci 2006;97:387-394) designated by the DEPOSITOR is required.
使用条件(日)			利用者は、研究成果の公表にあたって寄託者の指定する文献 (Cancer Sci 2006;97:387-394) を引用すること。
備考(英)
備考(日)
提供申込書類(英)			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日)			依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf
			提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料			手数料とお支払いについてはこちらをご覧ください。
細胞基本情報		寄託者	Sekido, Yoshitaka
		樹立者	Hida, Toyoaki
		寄託日	2006
		動物種	_human < Mammals
		属名	Homo
		種名	sapiens
		人種	Japanese
		性別	Male
		齢	59 years
		採取組織	malignant pleural mesothelioma, pleural fluid
		病名	malignant pleural mesothelioma
		細胞分類	cancer
		細胞寿命	infinite
		細胞形態	epithelial-like
		Cellosaurus(Expasy)	CVCL_5114
細胞培養・検査情報			寄託時情報	ロット情報
	培地・試薬情報		培地・試薬一覧はこちらをご覧ください。
		培養形態		Adherent cells
		培地		RPMI1640 + 10% FBS
		抗生物質		Free
		継代方法		0.25% Trypsin or (0.05% Trypsin + 0.53mM EDTA) or (0.25% Trypsin + 0.53mM EDTA)
		継代密度		1 : 6 split
		継代・培地交換頻度		Subculture : once/week, Medium Renewal : 2 times/week
		培養最適温度		37 ℃
		二酸化炭素濃度		5 %
		凍結培地		Medium + 10% DMSO
		凍結方法		Slow freezing
		マイコプラズマ/アコレプラズマ		(-)
		アイソザイム検査		LD, NP
		個体識別検査		OK
画像情報			寄託時情報	ロット情報
文献情報		Reference(英)	3件
		Reference(日)	0件
		利用者成果(英)	49件
		利用者成果(日)	0件

ページトップへ

Reference(英)

16469  Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade  Oncogene  2015  34(1):73-83  PubMed ID: 24336325   DOI: 10.1038/onc.2013.528

16471  Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes  Oncogene  2012  31(49):5117-22  PubMed ID: 22286761   DOI: 10.1038/onc.2012.5

3337  Usami, Noriyasu, Fukui, Takayuki, Kondo, Masashi, Taniguchi, Tetsuo, Yokoyama, Toshihiko, Mori, Shoichi, Yokoi, Kohei, Horio, Yoshitsugu, Shimokata, Kaoru, Sekido, Yoshitaka, Hida, Toyoaki  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.  Cancer Sci  2006  97:387-94  PubMed ID: 16630136   DOI: 10.1111/j.1349-7006.2006.00184.x

ページトップへ

Reference(日)

ページトップへ

利用者成果(英)

21627  Shimizu D, Ishibashi M, Yamada T, Toda Y, Hosogi S, Ashihara E.  POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.  Cancer Genomics Proteomics  2024  21(2):158-165  PubMed ID: 38423601   DOI: 10.21873/cgp.20437

21908  Ito M, Koido S, Iwamoto T, Morimoto S, Fujiki F, Sugiyama H, Matsumoto S, Effenberger C, Kiyotani K, Shiba K.  Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.  PLoS One  2024  19(8):e0308330  PubMed ID: 39116074   DOI: 10.1371/journal.pone.0308330

19895  Mori K, Matsumoto K, Ikeda M, Koguchi D, Shimizu Y, Tsumura H, Ishii D, Tsuji S, Sato Y, Iwamura M.  Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer  Diagnostics (Basel)  2023  13(19):3067  PubMed ID: 37835810   DOI: 10.3390/diagnostics13193067

19954  Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I.  Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma  Cancer Sci  2023  114(3):1095-1107  PubMed ID: 36369966   DOI: 10.1111/cas.15645

21089  Sakura K, Sasai M, Funaki S, Shintani Y, Okumura M, Kaneda Y.  Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study.  Cancers (Basel)  2023  15(3)  PubMed ID: 36765886   DOI: 10.3390/cancers15030929

21461  Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y.  SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.  Am J Surg Pathol  2023    PubMed ID: 37899530   DOI: 10.1097/PAS.0000000000002147

17590  Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A.  Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma  Front Cell Dev Biol  2022  10:945007  PubMed ID: 35903548   DOI: 10.3389/fcell.2022.945007

18220  Tatsumi S, Takeuchi M, Fujii T, Sugimoto A, Sekita-Hatakeyama Y, Nishikawa T, Uchiyama T, Morita K, Itami H, Takeda M, Yamazaki M, Ohbayashi C.  Evaluation of DNA/RNA quality from cell block of malignant mesothelioma and lung adenocarcinoma  Diagn Cytopathol  2022  50(6):273-283  PubMed ID: 35384396   DOI: 10.1002/dc.24960

20462  Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, Takeshima Y.  Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.  Oncol Rep  2022  47(2)  PubMed ID: 34859258   DOI: 10.3892/or.2021.8238

20093  Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F.  NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.  Cancers (Basel)  2021  13(7)  PubMed ID: 33805359   DOI: 10.3390/cancers13071561

20560  Abukar A, Wipplinger M, Hariharan A, Sun S, Ronner M, Sculco M, Okonska A, Kresoja-Rakic J, Rehrauer H, Qi W, Beusechem VWV, Felley-Bosco E.  Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A.  Cells  2021  10(12)  PubMed ID: 34944051   DOI: 10.3390/cells10123543

16120  Kanayama M, Oyama R, Mori M, Taira A, Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, Kato Y, Tanaka F.  Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma  Oncol Lett  2021  22(1):522  PubMed ID: 34025789   DOI: 10.3892/ol.2021.12783

6938  Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E.  Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition.  Mol Cancer Ther  2020  19(2):552-563  PubMed ID: 31619462   DOI: 10.1158/1535-7163.MCT-19-0356

12125  Fujii T, Itami H, Uchiyama T, Morita K, Nakai T, Hatakeyama K, Sugimoto A, Shimada K, Tsuji S, Ohbayashi C.  HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.  Biochem. Biophys. Res. Commun.  2020    PubMed ID: 32284171   DOI: 10.1016/j.bbrc.2020.03.172

13129  Kojima M, Kajino K, Momose S, Wali N, Hlaing MT, Han B, Yue L, Abe M, Fujii T, Ikeda K, Hino O.  Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.  Respir Res  2020    PubMed ID: 32677949   DOI: 10.1186/s12931-020-01449-2

13171  Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW.  Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.  Cancers (Basel)  2020    PubMed ID: 32824422   DOI: 10.3390/cancers12082310

13236  Jotatsu T, Izumi H, Morimoto Y, Yatera K.  Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis.  Oncol Rep  2020    PubMed ID: 33000251   DOI: 10.3892/or.2020.7778

13275  Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K.  Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion.  Sci Rep  2020    PubMed ID: 33028834   DOI: 10.1038/s41598-020-72448-y

13551  Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T.  Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells  FEBS Open Bio  2020  10(11):2375-2387  PubMed ID: 32961616   DOI: 10.1002/2211-5463.12985

13608  Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F.  Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2  Cells  2020  9(4):888  PubMed ID: 32260559   DOI: 10.3390/cells9040888

14504  Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y.  Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin  Oncol Lett  2020  19(6):4161-4168  PubMed ID: 32382354   DOI: 10.3892/ol.2020.11504

11413  Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, Kubota K, Gemma A.  Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.  Anticancer Res.  2019    PubMed ID: 30711938   DOI: 10.21873/anticanres.13156

11837  Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW.  Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.  Cancers (Basel)  2019    PubMed ID: 31597321   DOI: 10.3390/cancers11101502

12382  Yoneda K, Kuwata T, Chikaishi Y, Mori M, Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, Ichiki Y, Ohnaga T, Tanaka F.  Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma  Cancer Sci  2019  110(2):726-733  PubMed ID: 30499156   DOI: 10.1111/cas.13895

12383  Hino O, Abe M, Han B, Yan Y.  In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma  Cancer Sci  2019  110(5):1518-1524  PubMed ID: 30888083   DOI: 10.1111/cas.14001

10679  Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.  Capture of mesothelioma cells with 'universal' CTC-chip.  Oncol Lett  2018  15:2635-2640  PubMed ID: 29434985   DOI: 10.3892/ol.2017.7619

11150  Ohno Y, Shingyoku S, Miyake S, Tanaka A, Fudesaka S, Shimizu Y, Yoshifuji A, Yamawaki Y, Yoshida S, Tanaka S, Sakura K, Tanaka T.  Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.  Oncogene  2018  37(49):6357-6367  PubMed ID: 30061637   DOI: 10.1038/s41388-018-0405-y

11107  Xu D, Liang SQ, Yang H, Luthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW.  Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.  Br. J. Cancer  2018  119(1):65-75  PubMed ID: 29921948   DOI: 10.1038/s41416-018-0145-3

11217  Matsuura R, Kaji H, Tomioka A, Sato T, Narimatsu H, Moriwaki Y, Misawa H, Imai K, Tsuji S.  Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.  Sci Rep  2018    PubMed ID: 30250045   DOI: 10.1038/s41598-018-32534-8

7034  Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K.  HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.  Sci Rep  2017  7:45768  PubMed ID: 28361969   DOI: 10.1038/srep45768

10043  Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.  Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.  Lung Cancer  2017  104:98-105  PubMed ID: 28213009   DOI: 10.1016/j.lungcan.2016.12.017

10329  Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.  Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.  Front Genet  2017  8:70  PubMed ID: 28611824   DOI: 10.3389/fgene.2017.00070

19266  Shigeeda W, Shibazaki M, Yasuhira S, Masuda T, Tanita T, Kaneko Y, Sato T, Sekido Y, Maesawa C.  Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma  Oncotarget  2017  8(55):93729-93740  PubMed ID: 29212185   DOI: 10.18632/oncotarget.20750

14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786

14253  Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M.  Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma  Oncotarget  2017  8(26):42466-42477  PubMed ID: 28476017   DOI: 10.18632/oncotarget.17198

14627  Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F.  EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'  Oncol Rep  2017  37(1):77-82  PubMed ID: 27840987   DOI: 10.3892/or.2016.5235

9731  Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.  Establishment of anti-mesothelioma monoclonal antibodies.  BMC Res Notes  2016  9:324  PubMed ID: 27342200   DOI: 10.1186/s13104-016-2128-x

5814  Lourdes Cortes-Dericks, Laurene Froment, Gregor Kocher, Author information Article notes Copyright and License infor  Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines  Stem Cell Res Ther  2016  7:25  PubMed ID: 26861734   DOI: 10.1186/s13287-016-0282-7

10036  Jelena Kresoja-Rakic, Esra Kapaklikaya, Gabriela Ziltener, Damian Dalcher, Raffaella Santoro, Brock C Christensen, Kevin C Johnson, Beat Schwaller, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco  Identification of Cis- And Trans-Acting Elements Regulating Calretinin Expression in Mesothelioma Cells  Oncotarget  2016  7(16):21272-86  PubMed ID: 26848772   DOI: 10.18632/oncotarget.7114

12632  Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y.  Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma  Int J Oncol  2016  48(4):1599-607  PubMed ID: 26820394   DOI: 10.3892/ijo.2016.3358

12680  Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M, Takeshima Y.  Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia  Pathobiology  2016  83(1):33-40  PubMed ID: 26735863   DOI: 10.1159/000442092

13697  Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G.  Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity  BMC Cancer  2014  14:304  PubMed ID: 24884875   DOI: 10.1186/1471-2407-14-304

8088  Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.  Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.  Int. J. Cancer  2011  129:1005-17  PubMed ID: 20949562   DOI: 10.1002/ijc.25716

8199  Hasegawa S, Koshikawa-Yano M, Saito S, Morokoshi Y, Furukawa T, Aoki I, Saga T.  Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.  Int. J. Cancer  2011  128:2138-46  PubMed ID: 20617513   DOI: 10.1002/ijc.25547

19029  Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y.  LRRN4 and UPK3B are markers of primary mesothelial cells  PLoS One  2011  6(10):e25391  PubMed ID: 21984916   DOI: 10.1371/journal.pone.0025391

8186  Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.  Br. J. Cancer  2010  103:517-23  PubMed ID: 20628387   DOI: 10.1038/sj.bjc.6605786

8379  Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K.  Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.  Int. J. Cancer  2010  127:1948-57  PubMed ID: 20104519   DOI: 10.1002/ijc.25197

13735  Ito A, Hagiyama M, Mimura T, Matsumoto M, Wakayama T, Iseki S, Yokozaki H, Okada M.  Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium  Lab Invest  2008  88(5):504-14  PubMed ID: 18332875   DOI: 10.1038/labinvest.2008.15

16153  Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E.  Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity  Cancer Immun  2008  8:15.  PubMed ID: 19006261

ページトップへ

利用者成果(日)